secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2026-06-03T20:15:15+00:00
Accession:  0001193125-26-255467
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX and Regeneron expand collaboration; CytomX to receive $37M in target nomination payments
--------------------------------------------------------------------------------

- Amendment No. 4 adds up to eight new collaboration programs; Regeneron nominates first two.
- CytomX receives $37M aggregate target nomination payments for the two nominated programs.
- Total potential milestones under expanded agreement are up to approximately $4 billion.
- Royalty rates on global net sales unchanged; program selection period extended.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312526255467/0001193125-26-255467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312526255467/d66030d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-255467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer